We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Skin Biopsy Test Allows Clinicians to Look inside Nerves for Diagnosing Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 24 Mar 2023
Print article
Image: Syn-One Test is the only commercially available skin-based test that aids diagnosis of synucleinopathies (Photo courtesy of CND)
Image: Syn-One Test is the only commercially available skin-based test that aids diagnosis of synucleinopathies (Photo courtesy of CND)

The diagnosis of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy can pose significant challenges for clinicians. According to scientific studies, these disorders are misdiagnosed over 30% of the time, particularly during the early stages of presentation. Over the years, researchers have searched for biomarkers in the blood and spinal fluid and employed advanced radiographic methods to image neuron changes in the brain. However, these tests have not been sufficiently sensitive or specific, often failing to detect individuals with the diseases or indicating disease consistency in those who do not have them.

CND Life Sciences (Phoenix, AZ, USA) has developed the first-ever test in the market that can examine the nerves inside the human body and detect the protein accumulation in individuals with synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. These diseases are characterized by the accumulation of a misfolded protein called alpha-synuclein in the nervous system, which is unique to individuals with synucleinopathies.

The Syn-One Test is a minimally invasive skin biopsy (a punch biopsy with no stitches required) that provides physicians with visual evidence of these proteins accumulating within a patient’s nerves. Skin punch biopsy is an effective, reliable, non-invasive test for detecting such proteins, and can help find a cure for these neurodegenerative diseases. The reliability and effectiveness of this minimally invasive test have gained the attention of hundreds of clinicians across the US who are now using it as a diagnostic aid for the early detection of these synucleinopathies.

"Syn-One is changing the way clinicians diagnose many of these complex neurodegenerative diseases, and in parallel, biopharmaceutical companies are realizing how important it is to use Syn-One as a biomarker for clinical trials targeting alpha-synuclein," said Todd Levine, MD, CND's Chief Medical Officer and Co-Founder.

Related Links:
CND Life Sciences 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.